Clearwater Analytics (CWAN) agreed to buy Enfusion (ENFN) for $1.5 billion in cash and stock to expand its investment management platform.
Enfusion stockholders will get $11.25 a share comprising $5.85 in cash and $5.40 in Clearwater class A shares, the companies said Monday in a statement. Clearwater is expected to pay $760 million in cash and issue 23 million to 28 million new shares to Enfusion investors.
As part of the purchase price, Clearwater will also pay $30 million to terminate Enfusion's tax receivable agreement, the statement said.
Enfusion shares jumped 8.7% in recent Monday trading, and Clearwater fell 1.5%.
Price: 10.80, Change: +0.86, Percent Change: +8.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.